Display options
Share it on

J Pharm (Cairo). 2013;2013:381910. doi: 10.1155/2013/381910. Epub 2012 Nov 07.

Some Pharmacodynamic Aspects of Cefepime.

Journal of pharmaceutics

Mossad Gamaleddin Ahmed Elsayed, Ashraf Abdelhakim Ahmed Elkomy, Mohamed Elbadawy

Affiliations

  1. Pharmacology Department, Faculty of Veterinary Medicine, Benha University, P.O. Box 13736, Moshtohor, Toukh, Elqaliobiya, Egypt.

PMID: 26555975 PMCID: PMC4595966 DOI: 10.1155/2013/381910

Abstract

Some pharmacodynamic effects of cefepime, a new injectable semisynthetic cephalosporin, were studied in laboratory animals and the following results were obtained. Cefepime maximally stimulated isolated guinea pig's ileum, rat's colon (80 μg/mL bath), and rabbit's duodenum (400 μg/mL bath). Contrarily, complete relaxation of isolated rat's fundic strip was produced by 80 μg/mL bath. Effects of cefepime on isolated rat's uterine muscle were different according to stage of sex cycle. Cefepime did not induce any effects on the resting tonus of isolated guinea pig's tracheal chain and rabbit's aortic strip. Concentrations of 200 and 400 μg/mL bath induced marked inhibition in the force of muscular twitches of the isolated frog's gastrocnemius muscle which was less potent than that induced by procaine hydrochloride 2%. Cefepime completely blocked the neuromuscular transmission of frog's rectus abdominis muscle (40 μg/mL bath) and rat's phrenic nerve hemidiaphragm preparation (200 μg/mL bath). This blockade was reversed by acetylcholine and neostigmine. Cefepime produced dose-dependent negative inotropic effect on isolated rabbit's heart and guinea pig's auricles. There were no changes in blood pressure and rate of respiration in anaesthetized dog after cefepime injection. These findings indicate that cefepime has a low potential to produce adverse reactions at therapeutic doses.

References

  1. Jpn J Antibiot. 1986 Apr;39(4):958-78 - PubMed
  2. Jpn J Antibiot. 1979 Dec;32(12):1356-71 - PubMed
  3. Dtsch Tierarztl Wochenschr. 1997 Nov;104(11):481-7 - PubMed
  4. Arzneimittelforschung. 1980;30(10):1680-7 - PubMed
  5. J Cardiovasc Pharmacol. 2003 Jan;41(1):14-24 - PubMed
  6. Ann Pharmacother. 2009 Feb;43(2):220-7 - PubMed
  7. Neuropeptides. 1996 Aug;30(4):365-71 - PubMed
  8. Jpn J Antibiot. 1992 Jun;45(6):642-60 - PubMed
  9. Lancet Infect Dis. 2007 May;7(5):338-48 - PubMed
  10. Indian J Med Res. 1996 Sep;104:216-22 - PubMed
  11. Jpn J Antibiot. 1980 Oct;33(10):994-1018 - PubMed
  12. Jpn J Antibiot. 1990 Jul;43(7):1289-309 - PubMed
  13. Am J Cardiol. 1973 Feb;31(2):193-201 - PubMed
  14. J Microbiol Immunol Infect. 2007 Apr;40(2):134-40 - PubMed
  15. Braz J Med Biol Res. 2005 Jul;38(7):1113-22 - PubMed
  16. Jpn J Antibiot. 1984 Aug;37(8):1470-87 - PubMed
  17. Clin Infect Dis. 1993 Sep;17(3):369-79 - PubMed
  18. Am J Respir Med. 2003;2(1):75-107 - PubMed
  19. Pharmacol Rev. 1970 Sep;22(3):389-428 - PubMed
  20. Jpn J Antibiot. 1984 Jul;37(7):1428-39 - PubMed
  21. Jpn J Antibiot. 1992 Jun;45(6):661-80 - PubMed
  22. Eur J Pharmacol. 1995 Aug 25;282(1-3):177-84 - PubMed
  23. Jpn J Antibiot. 1982 Sep;35(9):2139-54 - PubMed
  24. Br J Pharmacol Chemother. 1946 Mar;1:38-61 - PubMed
  25. ANZ J Surg. 2006 Nov;76(11):1023-6 - PubMed
  26. J Pharm Pharmacol. 1990 Feb;42(2):115-20 - PubMed

Publication Types